California investment firm Frazier Healthcare Partners has gone over its hard cap target of $400 million as it looks to inject cash into early life science…
The involvement of the Big Pharmas helped BGV blast past its target, leaving it with €82 million to invest in life science companies in Europe.
Atlas-incubated Kymera Therapeutics has gotten off a $30 million series A and taken on Pierre Fabre’s R&D head as its new chief.
Oberland has signed up to make two milestone-based payments of $20 million each. In return, Impact will give Oberland predefined fedratinib royalties.
Despite 15 years of hurt for biopharma R&D in Alzheimer’s, AbbVie and Alector are still throwing in together to work on the disease.
Arsanis is gunning for a $58 million IPO as it seeks a new cash load for its work on using monoclonal antibodies for infectious diseases.
The antibody-drug conjugate specialist will use the money to take its two lead hematological cancer assets through registrational trials.
The series B round equips the Stanford University spinout to expand trials of its CD47-targeted approach to dialing up phagocytosis of cancer cells.
Big Pharma-backed antifibrotic startup Blade has triggered the remaining tranche of last summer’s $45 million series B after placing its bets on a leading…
Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund.